Operator

Welcome to Embla Medical Q1 2026 Conference Call. Today's call is being recorded. If you have any objections to this, please disconnect your line. [Operator Instructions]

I would like to introduce President and CEO, Sveinn Solvason; and CFO, Arna Sveinsdottir. Sveinn, please begin.

Sveinn Sölvason
President & CEO

Thank you very much. Good morning, and welcome to the Embla Medical conference call, where we will review the first quarter results for 2026. I'm Sveinn Solvason, President and CEO of Embla Medical. And joining me on today's call is our Chief Financial Officer, Arna Sveinsdottir; and Embla Medical's Head of Investor Relations, Klaus Sindahl. The presentation should take approximately 15 minutes, after which there will be an opportunity to ask questions during a Q&A session.

Now, if you would please go to the next slide. We are seeing good progress at the beginning of 2026. Sales in the first quarter amounted to $232 million, representing reported growth of 15% and organic growth of 4%. We delivered strong performance in Prosthetics & Neuro Orthotics, driven by continued momentum and solid volume growth across regions and categories. Growth in Bracing & Supports was moderate. And Patient Care experienced a soft quarter, largely driven by timing effects in Europe.

Our EBITDA margin for the quarter came in at 17% and is down 1 percentage point from the comparable quarter last year, largely due to external factors such as FX and tariffs. We delivered strong net profit growth, driven by growing operating results